Resmed

Resmed FCF/Debt

The Free Cash Flow to Debt Ratio of Resmed (RMD) as of Oct 14, 2026 is 570.60 %. In the previous year, Free Cash Flow to Debt Ratio was 248.65 % — a change of 129.48% (higher).

FCF/Debt

570.60 %

YoY

129.48%

Last updated:

Free Cash Flow to Debt Ratio of Resmed is 2026 570.60 % . Free Cash Flow to Debt Ratio of Resmed was 2025 248.65 % . It decreases by 129.48% higher compared to the previous year.

The Resmed FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
30.03 USD
Jan 1, 2020
59.21 USD
Jan 1, 2021
94.59 USD
Jan 1, 2022
25.17 USD
Jan 1, 2023
38.81 USD
Jan 1, 2024
181.90 USD
Jan 1, 2025
248.65 USD
Jan 1, 2026
570.60 USD
The Resmed FCF/Debt history
YEARFCF/DebtYoY
570.60 %+129.48%
248.65 %+36.70%
181.90 %+368.69%
38.81 %+54.20%
25.17 %-73.39%
94.59 %+59.76%
59.21 %+97.13%
30.03 %-80.50%
154.02 %+384.93%
31.76 %-22.41%
40.94 %-60.46%
103.54 %+0.43%
103.10 %—
Access this data via the Eulerpool API

Resmed Stock analysis

What does Resmed do? ResMed Inc. is a global leading provider of medical devices for the treatment of sleep disorders and respiratory diseases. The company was founded in Australia by Peter Farrell, a former employee of the University of New South Wales, in 1989. Today, ResMed is headquartered in San Diego, California, and employs over 7,500 people worldwide. Business model: ResMed's business model is based on providing medical products and solutions for the treatment of sleep apnea and other respiratory diseases. The company develops and distributes masks, devices, and accessories that help patients breathe better and achieve restful sleep. ResMed also offers cloud-based software solutions and services to assist doctors and sleep labs in diagnosing and monitoring patients. Products and divisions: ResMed's product range can be divided into four main divisions: Sleep & Respiratory Care, Software as a Service (SaaS), Technologies, and Dental Solutions. Sleep & Respiratory Care: In this division, ResMed offers a wide range of masks, devices, and accessories for the treatment of sleep apnea and other respiratory diseases. The most well-known products include the AirSense and AirMini devices, equipped with Automatic Sleep Detection and AutoSet algorithm to optimize respiratory pressure. ResMed also offers a range of CPAP masks, nasal and full face masks, as well as nasal pillow masks. Software as a Service (SaaS): ResMed's cloud-based software solutions and services are offered under the brand AirView. They include diagnostic tools, patient monitoring systems, and analysis tools. AirView allows doctors to access their patients' medical data captured by ResMed devices and monitor this data in real-time. Technologies: ResMed's Technologies division focuses on the development of advanced sensors for respiratory and sleep monitoring. Products include the S+, a smart sleep tracking system that operates without direct body contact, and the Reveal-LTE, an implant for monitoring heart and respiratory rates in patients with heart failure. Dental Solutions: ResMed has also developed products for dentistry to assist patients with mild to moderate upper airway obstruction. Products include the Narval CC, a custom-made dental device for the treatment of snoring and sleep apnea, and the Tap Pap nasal pillow oral appliance, a non-invasive mouthguard. Conclusion: ResMed is a leading provider of medical devices and solutions for the treatment of sleep apnea and other respiratory diseases. The company offers innovative products and technologies that help patients breathe better and achieve restful sleep. ResMed's cloud-based software solutions enable doctors to monitor their patients' health in real-time and develop effective diagnosis and treatment strategies. With its wide range of products, innovation, and highly qualified team of scientists, engineers, and medical professionals, ResMed will continue to play an important role in the healthcare industry. Resmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resmed stock

Free Cash Flow to Debt Ratio of Resmed is 570.60 % in 2026.

Free Cash Flow to Debt Ratio of Resmed changed from 248.65 % to 570.60 %, representing a 129.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Resmed since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Resmed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Resmed

All Key Metrics — Resmed